©2010 Baishideng.
World J Gastrointest Endosc. May 16, 2010; 2(5): 165-178
Published online May 16, 2010. doi: 10.4253/wjge.v2.i5.165
Published online May 16, 2010. doi: 10.4253/wjge.v2.i5.165
Table 6 Pharmacologic agents evaluated for potential reduction/prevention of post-ERCP pancreatitis
| Pharmacologic agent | RCT showed benefit |
| Allopurinol | Yes |
| Cephtazidime | Yes |
| Diclofenac | Yes |
| Gabexate | Yes |
| Glyceryl trinitrate | Yes |
| Hydrocortisone | Yes |
| Indomethacin | Yes |
| Interleukin-10 (IL-10) | Yes |
| Nafamostat mesylate | Yes |
| Octreotide | Yes |
| Somatostatin | Yes |
| Ulinastatin | Yes |
| Anticholinergic drugs | No |
| Aprotinin | No |
| Botulinum toxin | No |
| Calcitonin | No |
| Epinephrine | No |
| Fresh frozen plazma | No |
| Glucagon | No |
| H-2 Blocker | No |
| Heparin | No |
| Lidocaine | No |
| Methylprednisolone | No |
| N-aceytyl cysteine (NAC) | No |
| Natural beta-carotene | No |
| Nifedipine | No |
| Nitroglycerin | No |
| Parenteral nutrition | No |
| Pentoxifylline | No |
| Prednisone | No |
| Recombinant PAF acetylhydrolase (rPAF-AH) | No |
| Selenium | No |
| Semapimod | No |
- Citation: Woods KE, Willingham FF. Endoscopic retrograde cholangiopancreatography associated pancreatitis: A 15-year review. World J Gastrointest Endosc 2010; 2(5): 165-178
- URL: https://www.wjgnet.com/1948-5190/full/v2/i5/165.htm
- DOI: https://dx.doi.org/10.4253/wjge.v2.i5.165